1090dkk
0,0 %
Date:2024-10-09Time:09:06:37Latest report:Q2-2024List:SpotlightTicker:CURAS
Market Cap:225 mdkkEnterprise Value:227 mdkkNet Sales:- mdkkEarnings:-31,8 mdkkEmployees:0ISIN:DK0061295797

Ratios

10-year key figure history for Curasight turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Curasight with index and moving average MA50 and MA200.

Stockprice:10,90
MA50:10,77
MA200:12,76
Price/MA200:-14,6 %
RSI (14):53,1
Price/MA50:1,2 %

Description

Curasight is a Phase II clinical company based in Copenhagen, Denmark. The company is a pioneer in the field of using the Positron Emissions Tomography (PET) imaging platform targeted at the receptor uPAR, which is a known biomarker for cancer aggressiveness, which will be used for improved diagnosis in several types of cancer. PET imaging, usually combined with CT as PET / CT, is used to create images where the biology of the disease can be studied. The principle is that a radiolabeled tracer is injected and bound to the tissues, e.g. to a tumor, after which the radioactivity can be placed using a PET scanner.

Pharmaceuticals